跳至主要内容
临床试验/NCT05045417
NCT05045417Unknown不适用

IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage

Sohag University1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2021年10月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
140
试验地点
1
主要终点
SLE disease activity index (SLEDAI)

研究概览

简要总结

Many laboratory markers can be measured for assessment of Lupus activity as aberrant manufacturing and imbalance of the cytokines of T-helper cell which already have been implicated within autoimmunity pathogenesis as IL-18 and IL-10 levels are usually elevated in lupus sufferers and correlated with SLEDAI score IL-17 has been linked to immune-mediated organ damage in several autoimmune diseases and recently it has been linked to pathogenesis of a murine model of lupus and human lupus Diverse cytokine abnormalities which common in lupus patients may skew T cells differentiation into IL-17-producing CD4+ and double negative T cells. This could promote the autoimmune process by activation of immune cells &stimulation of proliferation of B-cell and production of antibody

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • SLE will be diagnosed according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE
  • Age ≥ 18 years.
  • Patients who are able and willing to give written informed consent

排除标准

  • Any other autoimmune disease rather than SLE. -
  • Systemic diseases
  • Malignancy
  • pregnancy

结局指标

主要结局

SLE disease activity index (SLEDAI)

时间窗: 18 Months

• Assessment of the disease activity in the patients will be done by using the SLE disease activity index (SLEDAI). It potentially measures reversible manifestations of the underlying inflammatory disease process. The scale includes24 "weighted" attribute grouped into 9 domains. The final score is the sum of all attributed scores. * No activity 0 * mild activity: 1-5 * moderate activity: 6- 1 0 * high activity : 1 1 - 1 9 * very high \> 20

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Aya Mohamed Ali

Assistant lecturer of rheumatology and rehabilitation sohag university hospitals

Sohag University

研究点 (1)

Loading locations...

相似试验